SCHEMBL7674946

SCHEMBL7674946

CS(=O)(=O)Nc1cc(CC(O)CNC(Cc2ccccc2)c2ccc3c(c2)OCO3)ccc1O

nearest known ligand 0.81

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 20/20 0.81
ADRB2 P07550 14/20 0.72
ADRB1 P08588 11/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7674944 1.00 ADRB3 (0.81) ADRB3ADRB2ADRB1
SCHEMBL7677204 0.95 ADRB3 (0.73) ADRB3ADRB2ADRB1
SCHEMBL7677199 0.95 ADRB3 (0.73) ADRB3ADRB2ADRB1
SCHEMBL7675836 0.93 ADRB3 (0.70) ADRB3ADRB2ADRB1
SCHEMBL7039407 0.90 ADRB3 (1.00) ADRB3
SCHEMBL7036847 0.90 ADRB3 (1.00) ADRB3
SCHEMBL7040290 0.90 ADRB3 (1.00) ADRB3
SCHEMBL7040876 0.90 ADRB3 (1.00) ADRB3
SCHEMBL7036850 0.90 ADRB3 (1.00) ADRB3
SCHEMBL7039903 0.90 ADRB3 (1.00) ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436914-B1 TREATING DIABETES, OBESITY, DEPRESSION, ACHALASIA OR INTESTINAL HYPERMOTILITY DISORDERS BRISTOL-MYERS SQUIBB COMPANY 2002-08-20 US claimed
US-20020026065-A1 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists SHER PHILIP M (US) 2002-02-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026065-A1 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists ADRB3, ADRB1, ADRA1A ADRB3 1/4885ADRB2 4/4885ADRB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.